✨ Free AI Report
Genentech, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Genentech, Inc.
Company Research

Genentech, Inc.: Business Overview, Financials & Competitive Analysis

Genentech, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Advancing obesity GLP-1/GIP compounds with strong clinical efficacy in a high-growth market, backed by significant Roche capital investment. Genentech demonstrates strong clinical validation and manufacturing commitment. Recent (January-May 2026) Phase II data shows CT-388 achieving 22.5% placebo-adjusted weight loss in obesity trials without reaching a plateau at 48 weeks. Strategic.

What is Genentech, Inc.'s industry? Genentech, Inc. (gene.com) operates in Drug Discovery Services. AskCyborg classifies Genentech, Inc. under Drug Discovery Services in its company registry.

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. A member of the Roche Group, the...

8/ 10Strong

Cyborg Score thesis

Advancing obesity GLP-1/GIP compounds with strong clinical efficacy in a high-growth market, backed by significant Roche capital...

Read the full analyst-debate transcript →
Industry Drug Discovery Services
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Genentech, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Genentech, Inc.

AskCyborg analysts argue the bull and bear cases for Genentech, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Genentech, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Genentech, Inc. Overview

Pro stress-test →

Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. A member of the Roche Group, the company has headquarters in South San Francisco, California. The organization operates with a unique dual identity: as part of the Roche portfolio while maintaining its own independent Research & Early Development group, allowing scientists to work freely and enhance innovation.

Strategic Profile

Pro stress-test →

Historically regarded as the world's first biotechnology company, Genentech is advancing multiple high-impact therapeutic areas including oncology, ophthalmology, and obesity. The company is executing significant capital investments to support growth, with a $2 billion manufacturing expansion in North Carolina set to be operational by 2029 to produce next-generation treatments for metabolic conditions such as obesity. This positions Genentech as a key driver of Roche's pharmaceutical innovation agenda.

Competitive Landscape

Pro stress-test →

Genentech competes in high-growth metabolic and ophthalmology markets against diversified competitors. In obesity/weight management, rivals include Novo Nordisk (GLP-1 products), Eli Lilly (oral GLP-1/GIP compounds), and Viking Therapeutics (VK2735). In ophthalmology, competitors include Novartis, Regeneron, and Apellis Pharmaceuticals in retinal disease treatment. Genentech's dual program approach (sequential GLP-1/GIP compounds, combination strategies) and integration within Roche's diagnostics/digital capabilities provide platform differentiation.

Industry Context

Genentech, Inc. operates in Drug Discovery Services.

Key facts

Founded: 1976 · Headquarters: South San Francisco, US · Employees: 13,539 (July 2021) · Revenue: N/A · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Genentech, Inc..

  • Moving both enicepatide and petrelintide into Phase III development while initiating a Phase II multi-arm combination trial in mid-2026
  • Showcasing strong ophthalmology portfolio data on Vabysmo®, Susvimo®, and investigational IL-6 inhibitor vamikibart across five retinal conditions including geographic atrophy and diabetic macular edema (April-May 2026)
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Announced positive Phase II results for CT-388 dual GLP-1/GIP receptor agonist showing 22.5% placebo-adjusted weight loss
  • January 2026Doubled manufacturing investment in Holly Springs, North Carolina facility to $2 billion
  • +2 moreTrack every material event for Genentech, Inc. as it happens. Explore monitoring →
Get alerted when Genentech, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

GLP-1/GIP therapiesLeading injectable GLP-1 agonist portfolio for obesity and diabetes→Oral GLP-1/GIP compoundsOral GLP-1 and dual GLP-1/GIP receptor agonists for diabetes and obesity→Retinal disease therapiesOphthalmology portfolio including treatments for macular degeneration and diabetic retinopathy→Complement inhibitorsTherapeutic protein platform including eye disease treatments→

Compare Genentech, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Genentech, Inc. operates in Drug Discovery Services. See how the rest of the sector scores on the Cyborg framework.

Browse Drug Discovery Services research →
NEW · MCP server

Ask your AI assistant about Genentech, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Genentech, Inc. and its top competitor on Cyborg Score”
“What did Genentech, Inc. do this quarter?”
“Is Genentech, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Genentech, Inc. do?+
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. A member of the Roche Group, the...
What is Genentech, Inc.'s Cyborg Score?+
Genentech, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Genentech, Inc.'s main competitors?+
Named competitors include GLP-1/GIP therapies, Oral GLP-1/GIP compounds, Retinal disease therapies, Complement inhibitors. The full competitive landscape is in the AskCyborg report.
How can I get the full Genentech, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Genentech, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Genentech, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.